FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Mylan 6-Item Form FDA-483 Posted

[ Price : $8.95]

FDA posts a six-item Form FDA-483 that led to a 12/19 Warning Letter to Mylan Laboratories citing its Pradesh, India manufacturing...

FDA Alert on Boston Accolade Pacers Early Replacement

[ Price : $8.95]

FDA alerts patients, caregivers, and healthcare providers to the potential for some Boston Scientific Accolade pacemakers to need ...

FDA Approves Xcoverys Ensacove for Some Lung Cancers

[ Price : $8.95]

FDA approves Xcoverys Ensacove, an anaplastic lymphoma kinase inhibitor, to treat some non-small cell lung cancers.

FDA Approves Humacytes Symvess

[ Price : $8.95]

FDA approves Humacytes Symvess for use with some extremity arterial injuries.

CRL for Zealands SBS Treatment NDA

[ Price : $8.95]

FDA issues a complete response letter for Zealands glepaglutide intended to treat short bowel syndrome.

Quality, Data Issues at Mylan Facility in India

[ Price : $8.95]

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

Boxed Warning for Veozah Liver Injury

[ Price : $8.95]

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

Hologic BioZorb Marker Recall Class 1: FDA

[ Price : $8.95]

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.

UCB Minzasolmin Parkinsons Study Misses Endpoints

[ Price : $8.95]

UCB says it is ending the development of minzasolmin, a drug it was working on with Novartis to treat early Parkinsons disease, af...

FDA Alert on Baxter Solution Sets

[ Price : $8.95]

FDA issues an alert against the use of certain Baxter Solution Sets with Duo-Vent Spikes because they were incorrectly assembled w...